… science areas, implemented in the development of novel diagnostic and therapeutic
strategies to advance the progress of personalized medicine and bridge the bench-to-bed gap. …

… dementia, amyotrophic lateral sclerosis, Parkinson’s disease, … of nanomedicine from bench
to bed side is also discussed. … Current medical therapies with advanced treatment modalities …

… Amyotrophic lateral sclerosis is a fatal neurodegenerative … currently no effective
disease-modifying treatment is available. A … medicine approaches to treat amyotrophic lateral …

… amyotrophic lateral sclerosis, specific cd markers and monocyte migration in osteoarthritis
and OA synovium, and finally the significance of digital twin technology for developing precise …

… treatment of ALS. These findings hold potential for facilitating the translation of research from
bench to bedside… Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. …

… Edaravone is indicated for treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's …
Medical uses Edaravone is used to treat patients with amyotrophic lateral sclerosis (ALS), which …

… Huntington’s disease, and amyotrophic lateral sclerosis, and relevant studies addressing
these … Nevertheless, the pharmacological impact of PG in amyotrophic lateral sclerosis remains …

… drug AmX0035 has beneficial effects on survival and function in people with amyotrophic
lateral sclerosis (… The two drugs individually exhibit neuroprotective properties in experimental …

… of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral
sclerosis … "clinical limits of amyotrophic lateral sclerosis" workshop contributors. J. Neurol. …

… The clinical manifestations of sporadic amyotrophic lateral sclerosis (sALS) and familial
amyotrophic lateral sclerosis (fALS) are almost very similar, and the median age of onset of sALS …